sofinnova ventures raises  million biotech venture fund employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       sofinnova ventures raises  million biotech venture fund tweet   am sofinnova raises  million biotech venture fund svp ix fund to invest primarily in latestage biopharmaceutical companies menlo park calif july   prnewswire  sofinnova ventures a menlo park based investment firm today announced the closing of sofinnova venture partners ix lp at the hard cap of  million and in excess of the initial fund target of  million sofinnova focuses exclusively on helping entrepreneurs build successful biotechnology companies consistent with recent funds svp ix will provide capital primarily to companies with promising later stage clinical programs along with select investments in earlier stage opportunities investments will focus on developing specialty pharmaceuticals and orphan disease products sofinnova intends to continue the firms successful strategy of sourcing investments in both the united states and europe sofinnova focuses exclusively on helping entrepreneurs build successful biotechnology companies consistent with recent funds svp ix will provide capital primarily to companies with promising later stage clinical programs along with select investments in earlier stage opportunities investments will focus on developing specialty pharmaceuticals and orphan disease products sofinnova intends to continue the firms successful strategy of sourcing investments in both the united states and europe we value the support that our returning limited partners and new investors have shown for our strategy and the sofinnova team commented jim healy general partner sofinnova sofinnova is proud to partner with talented entrepreneurs who are focused on developing innovative medicines that can positively impact patient care we remain committed to working with our collective network to identify and develop important new drugs build successful companies and continue to generate significant returns for our investors sofinnova recent ipos and exits include labrys acquired by teva zs pharma ipo zsph versartis ipo vsar aerie ipo aeri tesaro stock sale tsro sarcode acquired by shire nextwave acquired by pfizer intellikine acquired by takeda hyperion ipo hptx durata ipo drtx amarin stock sale amrn vicept acquired by allergan and preglem acquired by gedeon richter the partners of svp ix are srini akkaraju md phd jim healy md phd anand mehra md mike powell phd lars ekman md phd david kabakoff phd and jay shepard about sofinnova ventures sofinnova ventures has over  years of experience building life science companies into market leaders with  billion in committed capital the firm applies capital and expertise to take companies from inception to exit sofinnovas investment team of mds phds and seasoned executives has significant scientific operational and strategic experience and specializes in financing clinical therapeutics our team partners with entrepreneurs to build successful companies advance medicine and address patients unmet medical needs sofinnova is headquartered in menlo park ca with offices in la jolla ca and dublin ireland wwwsofinnovacom contact information jennifer james partner – investor relations and marketing sofinnova ventures   jennifersofinnovacom help employers find you check out all the jobs and post your resume read at biospacecom related news startup pixium vision hauls in  million led by sofinnova ventures candid advice for cashstrapped startups from a biotech vc success at lumena pharmaceuticals sofinnova ventures raises  million for life sciences taiho pharmaceutical invests us  million in remiges biopharma fund lp bruton announces  million investment in us healthcare venture capital fund sofinnova ventures stemcells inc stem announces closing of  million offering sofinnova ventures raises  million for biotechonly vc fund vc firm versant ventures closes in on  million fund for medtech and biotech garheng kong md phd joins sofinnova ventures as general partner national institutes of health nih has a new  million focus electroceuticals please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • sofinnova ventures   • biotechpharma  finance startup • biopharm executive  money talk                 sofinnova  wikipedia sofinnova from wikipedia the free encyclopedia jump to navigation search sofinnova is the name shared by two venture capital firms sofinnova ventures and sofinnova partners the name sofinnova is believed to be a contraction of the french société de financement de l’innovation or innovation venture capital company both firms trace their roots back to sofinnova sa an investment institution founded in paris in  the two firms have raised b since inception and shared a similar investment strategy of investing in the life science and technology sectors the two sister firms distinguish themselves on the basis of their target geographies and have been fully independent since  sofinnova ventures has offices in menlo park ca and san diego ca and focuses largely on us biotech investments with  allocation for europe sofinnova partners is based in paris and focuses primarily on european biotech and cleantech investments with a similar reciprocal allocation for the us sofinnova ventures and sofinnova partners have had historically some of the same limited partners and have coinvested together in selected companies including flamel cerep genset actelion preglem movetis ascendis obseva auris and nucana both firms work together in a collegial way to exchange information and due diligence in each others respective geographies the firms do not have an obligation to show each other deals or to coinvest but historically have coinvested together in  of their collective investments contents  sofinnova ventures usa  investments  sofinnova partners france  investments  history  s the founding of sofinnova  s the early growth of sofinnova  s the reorganization of sofinnova into sofinnova partners and sofinnova ventures  s the move to life science for sofinnova  s new growth initiatives at sofinnova  references  sofinnova ventures  sofinnova partners  external links sofinnova ventures usaedit sofinnova ventures type private industry private equity founded  headquarters menlo park ca united states key people jim healy md phd mike powell phd anand mehra md lars ekman md david kabakoff phd dan welch cory freeland phd tommy nguyen md phd nathalie auber hooman shalavi charlotte shropshire alain azan retired jean deleage deceased products venture capital total assets b number of employees  website wwwsofinnovacom sofinnova ventures is an independent venture capital firm based in menlo park with b capital under management investmentsedit sofinnova ventures has been an active venture investor investing in some wellknown venture investments of the period sofinnova invested in collagen aesthetics biogen genentech tandon tandem computers and printonix tumbleweed and phonecom sofinnova ventures funded several of these as startups that developed into large international companies more recently sofinnova ventures has backed companies including millennium pharmaceuticals kosan biosciences actelion intermune seattle genetics cotherix threshold pharmaceuticals prestwick preglem movetis intellikine amarin corporation salveo and labrys the san francisco office of sofinnova ventures was often remembered for having an original  ft mosasaurus in the office of one of the managing partners mike powell sofinnova ventures closed their san francisco office in  and combined their bay area offices into a single office on sand hill road in menlo park sofinnova ventures has raised several venture capital funds see table the earlier funds svp i through v were predominantly information technology it wherein the later funds were predominantly life science focused svp viii and ix were exclusively life science only with emphasis on phase  and  drug development svp iv was sofinnova ventures initial fund after the reorganization of sofinnova in  each of the funds from svp v through svp ix exceeded the target raise and closed at the maximum amount as allowed by the limited partner agreements year amount fund  m sofinnova venture partners i  m sofinnova venture partners ii  m sofinnova venture partners iii  m sofinnova venture partners iv  m sofinnova venture partners v  m sofinnova venture partners vi  m sofinnova venture partners vii  m sofinnova venture partners viii  m sofinnova venture partners ix source private equity intelligence and sofinnova sofinnova partners franceedit sofinnova partners type private industry private equity founded  headquarters paris france key people denis lucquin antoine papiernik rafaele tordjman graziano seghezzi henrijette richter monique saulnier jeanbernard schmidt retired jean deleage deceased products venture capital total assets € billion website wwwsofinnovafr sofinnova partners is an independent venture capital firm based in paris with approximately € billion of capital the firm invests in early stage companies and corporate spinoffs in clean technology and life science sofinnova has financed more than  companies in europe since inception  of which more than  have successfully completed an initial public offering and more than  have been acquired by strategic buyers investmentsedit following the separation of the two firms sofinnova partners completed fundraising for its third private equity fund sofinnova capital iii with €m among the investments in this fund are innate maximiles and novuspharma sofinnovas fourth fund which raised €m of capital made sofinnova one of the largest venture firms in europe at the time in  sofinnova partners was named “fund of the year” by private equity international and “vc techno house of the year ” by the european venture capital journal evcj which described sofinnovas fundraising as the “fundraising of the year ” this fund invested in a number of companies including taptu sofinnova partners has raised several venture capital funds see table year amount fund  €m sofinnova capital i  €m sofinnova capital ii  €m sofinnova capital iii  €m sofinnova capital iv  €m sofinnova capital v  €m sofinnova capital vi  €m sofinnova capital vii  €m sofinnova capital viii source private equity intelligence and sofinnova historyedit history of private equity and venture capital early history origins of modern private equity the s leveraged buyout boom the s leveraged buyout and the venture capital bubble the s dotcom bubble to the credit crunch v t e s the founding of sofinnovaedit   sofinnova was founded with the backing of several french financial institutions most notably crédit national and was notable at the time for creating the first american style venture capital firm in france peter brooke the founder of ta associates was a board member of sofinnova sa in its early years sofinnova sa quickly established a presence in the european market through the formation of sofinnova partners in paris sofinnova sa owned this firm from  until    sofinnova became the first european venture company to enter the us market launching its us affiliate sofinnova inc sofinnova ventures sofinnova cofounder jean deleage who would later cofound us venture firm burr egan deleage  co was appointed the head of the us operation sofinnovas us business gained attention for its role as an early backer of tandem computers and genentech in the early s   sofinnova cofounder jean deleage established the american subsidiary of sofinnova called sofinnova inc in san francisco which eventually became sofinnova ventures deleage departed sofinnova in  to cofound another venture capital firm burr egan deleage  co in  working with deleage sofinnova developed a partnership with burr egan deleage  co and ultimately other us firms jeanbernard schmidt who would later serve as chairman of sofinnova was named the head of us operations of sofinnova inc s the early growth of sofinnovaedit   sofinnova completed an initial public offering with a listing on the paris stock exchange   alain azan moved to san francisco to take over management of sofinnova ventures replacing jeanbernard schmidt schmidt would be named chairman of sofinnova retaining that position through  sofinnova ventures completed fundraising for svp i which was an private equity fund originally intended to invest in european companies expanding in the us ultimately sofinnova venture partners would shift its focus toward investments in domestic us companies   sofinnova partners completed fundraising for sofinnova capital its first private equity fund in france with €m of investor commitments sofinnovas investments in this fund include genset corporation as well as cerep egide and flamel s the reorganization of sofinnova into sofinnova partners and sofinnova venturesedit   sofinnova delisted itself from the paris exchange to raise capital privately through traditional private equity funds prior to the  reorganization sofinnova ventures raised three venture funds totaling m and sofinnova partners raised funds with €m in commitments   the global sofinnova organization restructured formally creating two separate management companies one for sofinnova ventures and one for sofinnova partners the reorganization was done on the basis of geography creating sofinnova ventures in the us and sofinnova partners in europe following a management buyout each of the management companies was solely owned by its respective management teams s the move to life science for sofinnovaedit   sofinnova ventures hires jim healy md phd and together he and mike powell phd rebuilt the sofinnova ventures ls brand with focus on clinical stage drug development companies   sofinnova ventures started its eirexecutive partner program in life sciences with its first eir barry selick following this several other eirsexecutive partners joined sofinnova ventures from then until  including jeff stein david kabakoff bill ringo strategic advisor goro takeda jay shepard george horner lars ekman and dan welch   sofinnova ventures and sofinnova partners first sponsored the sofinnova biopharm partnering conference in japan headed up by sofinnovas goro takeda in  the conference teamed up with biotechnology industry organization making this the largest biopartnering meeting in japan   svp vii was raised which was sofinnova ventures first fund that was overwhelmingly focused on life science  with emphasis on drug development their next fund svp viii in  was exclusively  life science at the same time sofinnova partners in paris moved from a balanced itls venture firm to one that was predominantly focused on life science   sofinnova ventures made its last it investment enovix the remaining it team was active for several years after this to monitor and monetize the final it investments s new growth initiatives at sofinnovaedit   sofinnova partners started their green seed fund and hired joško bobanović to manage this new initiative in  this seed fund initiative was announced in conjunction with the sofinnova capital vii announcement   sofinnova ventures worked with general partner garheng kong to spin out a new fund called healthquest capital hqcs mandate is to provide growth capital to companies transforming healthcare with a focus on companies other than drug development hqc raised their second fund at m in  and transitioned to further independence from the parent sofinnova ventures organization   sofinnova partners announced the first closing of sofinnova industrial biotech i at € million the fund dedicated to renewable chemistry follows a series of  investments in the sector since  it will leverage an experienced and dedicated team initially composed of denis lucquin managing partner joško bobanović partner michael krel principal and guillaume baxter senior associate referencesedit  a b c d based on capital raised since inception source private equity intelligence done deals venture capitalists tell their stories  p  the new venturers inside the highstakes world of venture capital  p  sofinnova sa public repurchase offering french sofinnova venturesedit sofinnova ventures business week profile distillations university of toronto sofinnova partnersedit accent to expand with investment from sofinnova partners external linksedit sofinnova ventures us  company website sofinnova partners france  company website v t e private equity and venture capital investment firms investment strategy venture growth mezzanine secondaries leveraged buyout history history of private equity and venture capital early history of private equity private equity in the s private equity in the s private equity in the s investors angel investor commercial bank corporate venture capital crowdfunding family office endowment fund of funds highnetworth individual institutional investor insurance company investment bank merchant bank pension fund sovereign wealth fund private equity firms venture capital firms portfolio companies retrieved from httpsenwikipediaorgwindexphptitlesofinnovaoldid categories companies established in companies based in san franciscoventure capital firms of the united stateslife sciences industryhidden categories pages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view about  sofinnova ventures home team portfolio about news contact healthquest capital sofinnova partners investor portal about us founded in  sofinnova is a clinicalstage biopharmaceutical venture capital firm with approximately b under management we are a passionate and committed team of mds and phds that deploy human and financial capital to improve the lives of patients through science our mission is to provide industry leading venture returns by delivering transformative medicines to patients we live our mission to deliver outstanding results for those we serve – patients entrepreneurs and the people and organizations that entrust us with their capital sofinnova specializes in clinical and late preclinical investments in biopharmaceutical products we actively partner with entrepreneurs across all stages of company formation including securing initial funding building successful management teams forming impactful corporate alliances and navigating the ma acquisition or ipos process we seek to build world class companies that aspire to dramatically improve the current state of medical care today and ultimately the lives of patients the history of sofinnova ventures sofinnova represents decades of active venture investing in silicon valley  our original french parent firm sofinnova sa was founded in paris in  and has the distinction of being one of the earliest venture capital firms in europe sofinnova moved into the us in  to build a transatlantic useu connection  jean deleage was the first president and founder of the us arm of sofinnova  sofinnova sa had great success in the us being an early investor in stellar companies such as tandem computers and genentech sofinnova sa initiated a new family of us venture funds in  aptly described as sofinnova venture partners i ii iii and more sofinnova invested the first three of these funds in primarily information technology and was known as a ‘boutique french vc firm’ until the late s each of these us sofinnova funds were raised invested and managed independently from the funds managed and invested by sofinnova in paris and both partnerships continued to be owned by sofinnova sa until the late s in  sofinnova restructured into two independent management firms sofinnova partners in paris and sofinnova ventures in san francisco each firm became an independent venture capital firm with independent funds investment strategies and partnerships it was the vision of the partners in  that each of the firms should be owned by the partners doing the investing allowing the carried interest profits to remain with the investing professionals aligning their interests with the limited partners who invest in the funds  that said the sister firms share deal flow expertise and due diligence information as well as invest together selectively on a casebycase basis since  sofinnova ventures has been almost exclusively life science focused and its two most recent funds svp viii and svp ix are exclusively life science   their biotech focus is on drug development mostly later stage with an emphasis on specialty pharma orphan drugs and rare diseases  key therapeutic areas include oncology respiratory neuro dermatology and areas where a primary sales force is not needed sofinnova ventures has a long track record of working closely with entrepreneurs to build leading biotech companies a more detailed history of the global sofinnova organization can be found here   sofinnova ventures inc contact  sofinnova ventures home team portfolio about news contact healthquest capital sofinnova partners investor portal contact information menlo park  sand hill road building  suite  menlo park ca  usa work telephone   fax fax   infosofinnovacom san diego  prospect street ocean level   la jolla ca  usa work telephone   fax fax   infosofinnovacom   sofinnova ventures inc about  sofinnova ventures home team portfolio about news contact healthquest capital sofinnova partners investor portal about us founded in  sofinnova is a clinicalstage biopharmaceutical venture capital firm with approximately b under management we are a passionate and committed team of mds and phds that deploy human and financial capital to improve the lives of patients through science our mission is to provide industry leading venture returns by delivering transformative medicines to patients we live our mission to deliver outstanding results for those we serve – patients entrepreneurs and the people and organizations that entrust us with their capital sofinnova specializes in clinical and late preclinical investments in biopharmaceutical products we actively partner with entrepreneurs across all stages of company formation including securing initial funding building successful management teams forming impactful corporate alliances and navigating the ma acquisition or ipos process we seek to build world class companies that aspire to dramatically improve the current state of medical care today and ultimately the lives of patients the history of sofinnova ventures sofinnova represents decades of active venture investing in silicon valley  our original french parent firm sofinnova sa was founded in paris in  and has the distinction of being one of the earliest venture capital firms in europe sofinnova moved into the us in  to build a transatlantic useu connection  jean deleage was the first president and founder of the us arm of sofinnova  sofinnova sa had great success in the us being an early investor in stellar companies such as tandem computers and genentech sofinnova sa initiated a new family of us venture funds in  aptly described as sofinnova venture partners i ii iii and more sofinnova invested the first three of these funds in primarily information technology and was known as a ‘boutique french vc firm’ until the late s each of these us sofinnova funds were raised invested and managed independently from the funds managed and invested by sofinnova in paris and both partnerships continued to be owned by sofinnova sa until the late s in  sofinnova restructured into two independent management firms sofinnova partners in paris and sofinnova ventures in san francisco each firm became an independent venture capital firm with independent funds investment strategies and partnerships it was the vision of the partners in  that each of the firms should be owned by the partners doing the investing allowing the carried interest profits to remain with the investing professionals aligning their interests with the limited partners who invest in the funds  that said the sister firms share deal flow expertise and due diligence information as well as invest together selectively on a casebycase basis since  sofinnova ventures has been almost exclusively life science focused and its two most recent funds svp viii and svp ix are exclusively life science   their biotech focus is on drug development mostly later stage with an emphasis on specialty pharma orphan drugs and rare diseases  key therapeutic areas include oncology respiratory neuro dermatology and areas where a primary sales force is not needed sofinnova ventures has a long track record of working closely with entrepreneurs to build leading biotech companies a more detailed history of the global sofinnova organization can be found here   sofinnova ventures inc news  sofinnova ventures home team portfolio about news contact healthquest capital sofinnova partners investor portal rss feed portfolio news june   art krieg comes down from the mountain with a m round for checkmate pharmaceuticals march   virtual biotech antiva sets out on a big rd quest armed with a m round for an hpv therapy march   bioclin therapeutics inc raises  million in series b financing led by sofinnova ventures and ysios capital january   obseva sa announces pricing of initial public offering january   obseva expands leadership team and board of directors with industry veterans december   novartis bolsters innovative dermatology portfolio through acquisition of ziarco group limited november   galera therapeutics receives m from sofinnova ventures november   galera therapeutics expands series b to  million july   dauntless takes flight with new business model for starting biotechs july   audentes announces ipo july   auris medical keyzilen granted fast track designation by fda july   coherus announces positive topline results june   auris makes front page on bio world auris gives assent may   coherus announces proposed public offering of common stock may   merus announces ipo past articles    sofinnova ventures inc sofinnova news september   heather behanna to speak at world antimicrobial resistance congress  may   sofinnova announces the addition of industry leader alan colowick md mph to its partnership april   jim healy to speak at cancer advance boston february   charlotte shropshire to speak at superreturn us west october   sofinnova steps up past articles  events december  jay shepard janssen labs annual trends in financing holiday industry panel december  mike powell acceleration  panel exits for life science companies october  sofinnova japan biopharma partnering conference september  mike powell  california biotech ceo conference “funding companies today” august  jim healy brookings expert workshop on limited use for drugs developed in an expedited manner to meet an unmet medical need media contact charlotte shropshire director of investor relations and marketing sofinnova ventures charlottesofinnovacom   bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version sofinnova ventures home team portfolio about news contact healthquest capital sofinnova partners investor portal partners for development equity in biotech sofinnova ventures news september   heather behanna to speak at world antimicrobial resistance congress  may   sofinnova announces the addition of industry leader alan colowick md mph to its partnership april   jim healy to speak at cancer advance boston february   charlotte shropshire to speak at superreturn us west october   sofinnova steps up october   sofinnova raises  million for oversubscribed fund x june   jim healy to speak at bio on market  political pressures portfolio news june   art krieg comes down from the mountain with a m round for checkmate pharmaceuticals march   virtual biotech antiva sets out on a big rd quest armed with a m round for an hpv therapy march   bioclin therapeutics inc raises  million in series b financing led by sofinnova ventures and ysios capital january   obseva sa announces pricing of initial public offering january   obseva expands leadership team and board of directors with industry veterans december   novartis bolsters innovative dermatology portfolio through acquisition of ziarco group limited november   galera therapeutics receives m from sofinnova ventures november   galera therapeutics expands series b to  million contact menlo park  sand hill road building  suite  menlo park ca  telephone   san diego  prospect street ocean level   la jolla ca  telephone   for inquiries please email infosofinnovacom for information about our sister firm sofinnova partners based in paris france please visit wwwsofinnovafr âšâ  sofinnova ventures inc team  sofinnova ventures home team portfolio about news contact healthquest capital sofinnova partners investor portal james healy mike powell anand mehra alan colowick lars ekman david kabakoff daniel welch nathalie auber heather behanna sarah bhagat eric delbridge tommy nguyen goro takeda alain azan hooman shahlavi james brody charlotte shropshire paul arata alfred yue alex chan kenny joo tina giangiacomoyogya tiffany davis jenn symmons josie kastelic rachel preston frances benson lesley weber alex dulnev team james healy general partner mike powell general partner anand mehra general partner alan colowick partner lars ekman executive partner private equity david kabakoff executive partner private equity daniel welch executive partner private equity nathalie auber partner and cfo heather behanna principal private equity sarah bhagat associate private equity eric delbridge portfolio manager public equity tommy nguyen associate portfolio manager public equity goro takeda venture partner alain azan founding partner hooman shahlavi partner  general counsel james brody chief compliance officer charlotte shropshire investor relations  marketing paul arata hr  administration alfred yue vice president finance alex chan senior accountant kenny joo financial analyst tina giangiacomoyogya events coordinator tiffany davis office manager  executive assistant jenn symmons executive assistant josie kastelic executive assistant rachel preston office assistant frances benson administrative receptionist lesley weber san diego office manager  executive assistant alex dulnev it manager âšâ  sofinnova ventures inc sofinnova ventures inc private company information  bloomberg july    pm et capital markets company overview of sofinnova ventures inc snapshot people company overview sofinnova ventures inc is a venture capital firm specializing in seed startup mid early stage series a first venture round and corporate spinouts it also considers investments in intermediate and later stage startup companies the firm does not invest in healthcare services toolkit companies diagnostics and neutraceuticals it seeks to invest in life sciences and information technology sectors in life sciences sector it seeks to invest in clinical stage pharmaceutical products companies biotechnology biopharmaceutical therapeutic drug or product companies in the late preclinical or phase i clinical stage drug companies to treat diseases with unmet medical needs drug disco sofinnova ventures inc is a venture capital firm specializing in seed startup mid early stage series a first venture round and corporate spinouts it also considers investments in intermediate and later stage startup companies the firm does not invest in healthcare services toolkit companies diagnostics and neutraceuticals it seeks to invest in life sciences and information technology sectors in life sciences sector it seeks to invest in clinical stage pharmaceutical products companies biotechnology biopharmaceutical therapeutic drug or product companies in the late preclinical or phase i clinical stage drug companies to treat diseases with unmet medical needs drug discovery platform technology clinicalstage compounds and medical technology companies for information technology investments it seeks to invest in product oriented it companies building new components systems or solutions enterprise software software targeting service providers and consumer opportunities and telecommunications infrastructure it invests in both sides of the atlantic with a focus on west coast in united states and can also consider investments in east coast of united states and european developed markets it seeks to make initial investments between  million and  million and total investments between  million and  million over the life of a company for technology companies and makes initial investments between  million and  million and total investments between  million and  million for life science companies the firm seeks to make seedstage investments in both life science and technology between  million and  million to incubate promising technologies out of academia or industry the firm requires a board seat whenever it invests in early stage companies as a lead or colead investor sofinnova ventures inc was founded in  and is based in menlo park california with additional offices in la jolla california and tokyo japan detailed description  sand hill roadbuilding suite menlo park ca united statesfounded in  phone  fax  wwwsofinnovacom key executives for sofinnova ventures inc mr alain l azan founding partner dr garheng kong md phd mba founder and managing partner age  mr james brody chief compliance officer and chief operations officer mr hooman shahlavi jd partner and general counsel dr james i healy md phd general partner managing partner and partner age  compensation as of fiscal year  sofinnova ventures inc key developments sofinnova ventures inc presents at boston ceo conference may  pm may   sofinnova ventures inc presents at boston ceo conference may  pm venue four season boston  boylston street boston ma  united states speakers james i healy general partner managing partner and partner sofinnova ventures inc presents at bio international conference  jun  am may   sofinnova ventures inc presents at bio international conference  jun  am venue san diego convention center san diego ca  united states speakers james i healy general partner managing partner and partner sofinnova appoints sunil agarwal as partner oct   sofinnova announced the addition of dr sunil agarwal to the investment team as a partner prior to joining sofinnova sunil was the executive vice president and chief medical officer for ultragenyx he currently serves on the board of directors for myokardia and calithera biosciences similar private companies by industry company name region visory llc united states  road partners llc united states t partners llc united states jumpcom inc united states  ontario inc united states recent private companies transactions typedate target private placement june   checkmate pharmaceuticals inc private placement may   iterum therapeutics limited mergeracquisition may   mirna therapeutics inc request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact sofinnova ventures inc please visit wwwsofinnovacom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close sofinnova venture partners ix lp private company information  bloomberg july    pm et capital markets company overview of sofinnova venture partners ix lp snapshot people company overview sofinnova venture partners ix lp specializes in latestage and earlierstage companies the fund seeks to make select investments in early stage businesses it seeks to invest in biopharmaceuticals including specialty pharmaceuticals orphan drugs orphan disease products and clinical drug development companies in the united states and europe  sand hill roadbuilding suite menlo park ca united statesfounded in  phone  fax  key executives for sofinnova venture partners ix lp dr james i healy md phd partner age  dr michael f powell phd partner age  dr anand mehra md partner age  dr srinivas akkaraju md phd partner age  compensation as of fiscal year  similar private companies by industry company name region visory llc united states  road partners llc united states t partners llc united states jumpcom inc united states  ontario inc united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact sofinnova venture partners ix lp please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close active investments portfolio  sofinnova ventures home team portfolio about news contact healthquest capital sofinnova partners investor portal active investments selected realized investments remaining it investments active investments aclaris therapeutics specialty pharmaceutical dermatology company focused on the development of novel dermatologic therapies nasdaq acrs aerie pharmaceuticals clinicalstage biotechnology company dedicated to the discovery and development of novel treatments for glaucoma nasdaq aeri alimera sciences specializes in the research development and commercialization of prescription ophthalmic pharmaceuticals nasdaq alim amarin focused on improving the treatment of cardiovascular disease the company’s cardiovascular programs capitalize on its expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in treating cardiovascular disease nasdaq amrn anthera pharmaceuticals focused on developing and commercializing products to treat serious diseases associated with inflammation including cardiovascular and autoimmune diseases nasdaq anth antiva develop creatively designed therapeutics that dramatically improve health outcomes for patients suffering from diseases caused by hpv and other viruses ascendis pharma ascendis pharma develops differentiated prodrug versions of highvalue protein drugs such as growth hormone nasdaq asnd atyr pharma focused on the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology a newly discovered set of physiological modulators nasdaq life audentes therapeutics committed to the development and commercialization of innovative new treatments for people with serious rare diseases through the application of gene therapy technology nasdaq bold auris medical prevention or treatment of inner ear disorders for acute inner ear tinnitus and for acute inner ear hearing loss nasdaq ears bioclin therapeutics our strategy is to develop biologics for medical conditions where there has been no approved or satisfactory therapy our lead product b is a human antibody targeting fgfr fibroblast growth factor receptor  being developed as a treatment for metastatic bladder cancer and achondroplasia dwarfism catalyst biosciences creating novel catalytic biopharmaceutical products based on engineered human proteases checkmate pharmacueticals developing novel approach to specifically activating the immune system to recognize and ultimately destroy tumor cells chiasma latestage biotech developing an oral drug candidate for acromegaly nasdaq chma coherus biosciences a leading developer of highquality therapeutics with a robust pipeline of biosimilar products nasdaq chrs dauntless pharmaceuticals biopharmaceutical company focused on the development of specialty drugs edge therapuetics develops commercialize novel hospitalbased therapies capable of transforming treatment paradigms in the management of acute lifethreatening neurological conditions nasdaq edge first aid shot therapy focused on the development and commercialization of a comprehensive portfolio of otc pharmaceutical products in liquid shot format galera therapeutics galera therapeutics is a private clinicalstage biotech company focused on the development of breakthrough drugs targeting the oxygen metabolic pathways histogenics combining cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration nasdaq hsgx hyperion therapeutics focused on the development of treatments that address critical unmet needs in the areas of gastroenterology and hepatology nadsaq hptx innocoll developing and manufacturing a range of pharmaceutical products and medical devices using its proprietary collagenbased technologies nasdaq innl merus clinicalstage immunooncology company developing innovative bispecific antibody therapeutics to treat and potentially cure cancer patients mirna therapeutics developing tumor suppressor micrornas mirnas to kill cancer cells by regaining control over multiple oncogenic pathways nasdaq mirn natera develops and commercializes noninvasive methods for analyzing dna nucana developing and commercialising novel anticancer medicines including next generation nucleotide prodrugs obseva dedicated to the development of innovative drugs for women’s reproductive medicine including preterm labor ocera focused on the development of drugs to treat a broad range of gastrointestinal and liver diseases nasdaq ocrx ophthotech corporation specializing in the development of novel therapeutics to treat diseases of the eye nasdaq opht principia biopharma focused on discovering and developing firstinclass small molecule drugs within the fields of autoimmune disease and oncology that are potent and safe prothena advancing and developing novel antibodies for broad range of diseases involving protein misfolding or cell adhesion including amyloidosis nasdaq prta spark therapeutics focused on developing curative onetime gene therapy products including lead gene therapy candidate for rperelated blindness nasdaq once versartis developing therapeutics for the treatment of endocrine disorders including human growth hormones nasdaq vsar ziarco ziarco is a private clinical stage biotechnology company developing products to treat chronic inflammatory diseases with a focus on inflammatory skin disorders in particular atopic dermatitis and psoriasis these diseases impact the wellbeing of millions of children and adults globally by severely reducing quality of life zs pharma focused on the treatment of kidney and liver diseases including hyperkalemia nasdaq zsph   sofinnova ventures inc active investments portfolio news june  art krieg comes down from the mountain with a m round for checkmate pharmaceuticals march  virtual biotech antiva sets out on a big rd quest armed with a m round for an hpv therapy march  bioclin therapeutics inc raises  million in series b financing led by sofinnova ventures and ysios capital january  obseva sa announces pricing of initial public offering january  obseva expands leadership team and board of directors with industry veterans december  novartis bolsters innovative dermatology portfolio through acquisition of ziarco group limited november  galera therapeutics receives m from sofinnova ventures november  galera therapeutics expands series b to  million july  dauntless takes flight with new business model for starting biotechs sofinnova ventures beats fund ix target with  mln  pe hub subscribe to pe hub wire join over  of your peers get the mustread email for pevc professionals delivered to your inbox daily — for free us edition daily canada edition weekly we will not send you spam and we dont share your email address with rd parties i accept the terms and conditions subscribe yes no registersign in a community for professionals in private capital sofinnova ventures beats fund ix target with  mln july   by chris witkowsky follow chriswitkowsky print email share via email separate multiple email addresses with commas share send me a copy email preview to from subject look at this story on pe hub sofinnova ventures beats fund ix target with  mln sofinnova ventures has closed its ninth fund on its  million hard cap beating its original target of  million the firm announced continue reading on pe hub writes sofinnova ventures has closed its ninth fund on its  million hard cap beating its original target of  million the firm announced sofinnova venture partners ix lp was in fundraising for about five months according to a person with knowledge of the process the firm did not use a placement agent vcj and affiliated website pehub reported on july  that the firm was in the market the tally of lps is unknown but the new fund has received a  million from massachusetts pension reserves investment management board and the illinois teachers’ retirement system also reportedly approved a commitment of  million to the fund in june according to pensions  investments sofinnova ventures has done a good job sticking with its core strategy and maintaining size discipline in its fund sizes according to lisa edgar a managing director at top tier capital partners a san franciscobased lp in the fund “it can be hard to make money in this space but they’ve been successful in doing that in such a way they had a lot of existing investors come back” edgar said sofinnova based in menlo park california with offices in la jolla california and dublin ireland primarily targets latestage clinical drug development companies in the united states and europe as well sofinnova will make “select investments” in earlier stage opportunities the firm said its investment focus is on developing specialty pharmaceuticals and orphan disease products the firm said “we remain committed to working with our collective network to identify and develop important new drugs build successful companies and continue to generate significant returns for our investors” jim healy general partner at sofinnova said in the statement sofinnova closed its eighth fund in  on  million and its seventh fund on  million in  fund vii was generating a x multiple and a  percent internal rate of return as of march   according to information from the oregon public employees retirement fund fund viii was producing a x multiple according to oregon’s information though the system did not provide an irr partners on fund ix are srini akkaraju jim healy anand mehra mike powell lars ekman david kabakoff and jay shepard akkaraju is the newest member of the team he joined sofinnova in  as a general partner prior to sofinnova ventures akkaraju was a managing director at new leaf venture partners before that he was a cofounder and managing director at panorama capital prior to which he was a partner at jpmorgan partners in may sofinnova ventures led a  million series b funding in spark therapeutics a latestage company developing genebased medicines for certain diseases other investors in the funding round included brookside capital deerfield management company rock springs capital funds and accounts managed by t rowe price associates and two undisclosed healthcare funds photo courtesy of shutterstock print email share via email separate multiple email addresses with commas share send me a copy email preview to from subject look at this story on pe hub sofinnova ventures beats fund ix target with  mln sofinnova ventures has closed its ninth fund on its  million hard cap beating its original target of  million the firm announced continue reading on pe hub writes dont miss out meet new and diverse managers in private equity venture capital and real estate at the third emerging manager connect east at new york citys harvard club click here for details sign up to our newsletter receive updates from our pe hub wire and top stories of the week newsletters first name last name email address us edition daily canada edition weekly we will not send you spam and we dont share your email address with rd parties i accept the terms and conditions you are now subscribed to the pehub wire and top stories of the week newsletters buyouts insiderargosy group llc produces several free newsletters that are sent directly to the email you provide at registration namely pe hub wire pe hub canada wire pe hub wire top story of the week buyouts daily and vcj alert to enable us to keep providing these services free of charge we reserve the right to contact you with special invitations to sample or purchase private equityrelated products by submitting this free subscription request for any of these products you are also consenting to this communication should you ever wish to unsubscribe from a particular communication you may activate the unsubscribe mechanism at the bottom of the email this will discontinue both the special invitations mentioned previously as well as your subscription to the weekly newsletter the information you provide will be safeguarded by argosy group llcbuyouts insider the company’s subsidiaries may use it to keep you informed of relevant products and services we occasionally allow reputable companies outside of the company to mail details of products which may be of interest to you as an international group we may transfer your data on a global basis for the purposes indicated above we will never share your email or contact details with any outside company however should you have any questions please do not hesitate to contact us email protected top posts new oil and gas company native racks up  mln by iris dorbian kkr to buy nature’s bounty from carlyle by luisa beltran blackrock leads funding round for fintech platform icapital by iris dorbian platinum equity to buy united site services by luisa beltran the pe hub podcast episode two by staff report private equity jobs of the week priceline kpmg novaquest are hiring by eamon murphy the carveout curveball by pehublogger network raymond james expands team with new hire by iris dorbian microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft weblp login menlo park login to weblp v please provide the following information forgot password need support emailfinancesofinnovacom copyright  efront    all rights reserved open source licenses copyright  efront    all rights reserved this product includes the following libraries which are covered by the mit license jquery jquery ui jplayer dropdown check list jquery mouse wheel html placeholder jquery plugin simplemodal jquery validation plugin jscrollpane jquery color picker devageservicemodel pdfsharp in public domain json covered by the mspl license yahoo yui compressor for net expression tree serializer ioniczip covered by microsoft limited public license report viewer sync framework covered by apache  license lognet castlecore castledynamicproxy covered by gnu lesser general public license nhibernate object relational mapper iesicollections nhibernatelinq nhibernatebytecodecastle covered by code project open license compactformatterplus adohelper binary serializerdeserialzer covered by bsd license antlr fluent nhibernate covered by bsd clause license msbuild community tasks covered by zliblibpng license nunit microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft sofinnova raises  million biotech venture fund sofinnova raises  million biotech venture fund svp ix fund to invest primarily in latestage biopharmaceutical companies jul    et from sofinnova ventures sofinnova ventures logo prnewsfotosofinnova ventures     facebook twitter pinterest sofinnova ventures logo prnewsfotosofinnova ventures menlo park calif july   prnewswire  sofinnova ventures a menlo park based investment firm today announced the closing of sofinnova venture partners ix lp at the hard cap of  million and in excess of the initial fund target of  million sofinnova focuses exclusively on helping entrepreneurs build successful biotechnology companies consistent with recent funds svp ix will provide capital primarily to companies with promising later stage clinical programs along with select investments in earlier stage opportunities investments will focus on developing specialty pharmaceuticals and orphan disease products sofinnova intends to continue the firms successful strategy of sourcing investments in both the united states and europe we value the support that our returning limited partners and new investors have shown for our strategy and the sofinnova team commented jim healy general partner sofinnova sofinnova is proud to partner with talented entrepreneurs who are focused on developing innovative medicines that can positively impact patient care we remain committed to working with our collective network to identify and develop important new drugs build successful companies and continue to generate significant returns for our investors sofinnova recent ipos and exits include labrys acquired by teva zs pharma ipo zsph versartis ipo vsar aerie ipo aeri tesaro stock sale tsro sarcode acquired by shire nextwave acquired by pfizer intellikine acquired by takeda hyperion ipo hptx durata ipo drtx amarin stock sale amrn  vicept acquired by allergan and preglem acquired by gedeon richter the partners of svp ix are srini akkaraju md phd jim healy md phd anand mehra md mike powell phd lars ekman md phd david kabakoff phd and jay shepard about sofinnova ventures sofinnova ventures has over  years of experience building life science companies into market leaders with  billion in committed capital the firm applies capital and expertise to take companies from inception to exit sofinnovas investment team of mds phds and seasoned executives has significant scientific operational and strategic experience and specializes in financing clinical therapeutics our team partners with entrepreneurs to build successful companies advance medicine and address patients unmet medical needs sofinnova is headquartered in menlo park ca with offices in la jolla ca and dublin ireland wwwsofinnovacom contact informationjennifer jamespartner – investor relations and marketingsofinnova ventures  jennifersofinnovacom logo  httpphotosprnewswirecomprnhsflogob source sofinnova ventures related links httpwwwsofinnovacom view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more jan    et preview sofinnova ventures adds daniel g welch to life science investing team jul    et preview sofinnova promotes jennifer james to partner my news release contains wide tables view fullscreen looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search